Peptides for muscle growth: Phase III data to preclinical — ranked without the marketing framing.

The peptides marketed for muscle growth span an enormous evidence range — from MK-677, which has Phase III-equivalent data for lean mass in elderly cohorts, to follistatin-344 and myostatin inhibitors, which are preclinical with concerning oncogenic signals in murine models. Understanding where each compound sits on the translational ladder, and what the human trials actually measured, is the whole task.

The five categories of muscle-growth compounds

Muscle-growth peptides fall into five mechanistic categories with very different evidence profiles. The GH secretagogue family (MK-677, Ipamorelin, CJC-1295) has the most human data — it is also the family where the existing evidence was collected in elderly or GH-deficient populations, not in healthy young adults pursuing hypertrophy. The IGF-1 axis family (IGF-1 LR3, DES, MGF) operates through the most direct anabolic signal in muscle biology but has no human trial data. The myostatin inhibitor family (follistatin-344, ACE-031) has dramatic animal data and a cautionary human clinical story. BPC-157 and TB-500 appear in this context on the basis of tissue-repair rationale, not anabolic evidence. And GLP-1 agonists appear as the problem the anabolic peptides are sometimes proposed to solve.

MK-677: the evidence in full

MK-677 (ibutamoren mesylate) is a ghrelin mimetic and growth hormone secretagogue receptor (GHSR) agonist. Unlike peptide GH secretagogues, it is orally bioavailable — the pharmacological feature that explains its market dominance relative to injected alternatives. Smith et al. (1993, Science) characterised the GHSR and established the receptor basis for the compound class.

The landmark efficacy study is Nass et al. (2008, Annals of Internal Medicine), a randomised, double-blind, placebo-controlled, Phase III-equivalent trial in 65 healthy adults aged 60–81 (mean age 69). Participants received MK-677 25 mg/day orally or placebo for 12 months; DEXA measured body composition. Results: IGF-1 increased approximately 60%; lean body mass increased 1.6 kg (p<0.05) vs placebo; fat mass did not change significantly. The 1.6 kg lean mass increment requires careful interpretation. DEXA-measured lean mass includes skeletal muscle, bone mineral, and extracellular water. MK-677 increases plasma volume and causes clinically significant fluid retention — a known side effect of GH excess — and the Nass trial lean-mass increment likely reflects a mixture of fluid and muscle components. MK-677 is not a pure muscle-building signal even in its best available trial.

Svensson et al. (1998, J Clin Endocrinol Metab) showed that 2-year MK-677 treatment in GH-deficient adults increased IGF-1, lean mass, and reduced fat mass — but GH-deficient adults have a pharmacologically different starting point than the GH-sufficient young adult pursuing hypertrophy. The anabolic effect of GH restoration in somatopause is not the same as the effect of GH supraphysiology in a healthy 25-year-old. Full MK-677 coverage is in our MK-677 (ibutamoren) page in the Longevity cluster.

CJC-1295 and Ipamorelin: GH pulses, not muscle-growth RCTs

CJC-1295 is a GHRH analog with a drug affinity complex (DAC) modification that extends half-life from minutes (native GHRH: ~5 min) to approximately 6–8 days, enabling sustained tonic GH axis stimulation. Teichman et al. (2006, J Clin Endocrinol Metab) reported Phase II results in 21 healthy adults: subcutaneous CJC-1295 (30–60 µg/kg, single dose or multiple doses over 28 days) produced sustained IGF-1 elevation and mean GH increases of 2–10-fold over baseline. The trial measured PK and GH/IGF-1 levels — it was not a muscle-growth efficacy trial.

Our Ipamorelin research page covers the compound's Phase II data from its development as NNC 26-0161, a selective GHRP for post-operative GI motility — not muscle growth. The combination of CJC-1295 and Ipamorelin is the most commonly used GH-secretagogue stack in the research community because CJC-1295 provides a sustained GHRH-like signal while Ipamorelin provides an acute GHRP-like pulse, theoretically producing a physiologically mimicked combined GHRH + GHRP stimulation pattern. The published human data supports GH and IGF-1 elevation; the muscle-growth endpoint is an inference. Full GH-axis coverage — including Sermorelin, GHRP-2, GHRP-6, and Hexarelin — is in the Longevity & GH Axis pillar. CJC-1295 has its own spoke at CJC-1295.

IGF-1 LR3 and IGF-1 DES: compelling physiology, no human trial

IGF-1 LR3 is a recombinant IGF-1 analog with an N-terminal 13-amino-acid extension and an Arg3 substitution that reduces binding affinity to IGF-binding proteins (IGFBPs), extending plasma half-life from approximately 10–12 minutes (native IGF-1) to 20–30 hours. IGF-1 DES is the des(1–3)IGF-1 fragment — truncated at the N-terminus — which similarly reduces IGFBP binding and increases potency at the IGF-1 receptor (IGF1R). Both activate the downstream PI3K/Akt/mTOR and MAPK pathways that drive satellite-cell activation, protein synthesis, and muscle hypertrophy.

The physiology is compelling: IGF-1 is the primary downstream mediator of GH-driven muscle anabolism. Wilkes et al. (2009, Clin Sci) showed IGF-1 infusion increased muscle protein synthesis in young healthy humans. The research-peptide community's interest is built on (a) the correct receptor target; (b) rodent satellite-cell activation data; (c) the inference that exogenous IGF-1 LR3 can replicate endogenous GH → IGF-1 → muscle anabolism more directly. What this chain cannot answer: whether supraphysiologic IGF-1 receptor activation in healthy adults increases muscle mass safely, and whether it carries proliferative risks at the doses used in research settings. Full coverage: our IGF-1 LR3 research page and mechano-growth factor page.

Myostatin inhibitors: dramatic biology, cautionary clinical story

Myostatin (GDF-8) is a TGF-β superfamily member that functions as a negative regulator of skeletal muscle mass. Lee and McPherron (2001, PNAS) showed that myostatin knockout mice develop approximately double the muscle mass of wild-type animals; natural human myostatin-inactivating mutations produce extreme muscularity. The biology is real and dramatic.

ACE-031 is a recombinant fusion protein (ActRIIB-Fc) that traps myostatin, activin A, and related TGF-β family ligands. Attie et al. (2013, J Clin Endocrinol Metab) published a Phase II trial in 48 postmenopausal women: lean mass increased 3.3% vs placebo over 8 weeks. However, the trial was halted because of adverse events — nosebleeds and telangiectasias — consistent with off-target inhibition of bone morphogenetic protein (BMP) signalling through the shared ActRIIB receptor. The safety signal illustrates a fundamental pharmacological problem: non-selective ActRIIB blockade affects vascular, cardiac, and reproductive TGF-β family signalling alongside muscle myostatin.

Follistatin-344, an endogenous myostatin antagonist isoform, is at an earlier stage. The RUO research-chemical market sells "follistatin-344" as a lyophilized powder, but follistatin is a 344-residue glycoprotein that is extraordinarily difficult to produce correctly — protein folding, disulfide bonds, and glycosylation are required for biological activity. Vendor authenticity and product quality in this category are far more uncertain than for simple synthetic peptides like BPC-157. See our follistatin-344 page, myostatin inhibitor peptides, and ACE-031 page for fuller treatment.

The GLP-1 muscle-loss tangent

Semaglutide and tirzepatide produce 15–22% body-weight reduction over 68–72 weeks in landmark trials. Lean mass loss accompanies fat loss at a ratio of approximately 25–40% lean to 60–75% fat — so patients losing 20 kg may lose 5–8 kg of lean mass. This is a clinically significant sarcopenic risk, particularly in older adults who have less lean mass reserve.

This has generated research interest in pairing GLP-1 drugs with GH-axis or anabolic peptides to preserve muscle during weight loss. The mechanistic rationale is sound: GH axis stimulation increases IGF-1 and promotes protein synthesis, potentially offsetting lean-mass erosion from caloric restriction. The published evidence for this specific combination remains early. For the full GLP-1 story, our semaglutide page covers the landmark STEP and SELECT trial data; the BPC-157 in bodybuilding contexts spoke covers adjacent territory.

Summary table

The full cluster map — with evidence tiers for all 30 spokes in this pillar — is in the Muscle & Recovery pillar. Adjacent territory in the Longevity cluster covers the GH-axis compounds (MK-677, CJC-1295, GHRP variants) in greater pharmacological depth.